Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective.
Xiaoming JiaJing LiuAnurag MehtaChristie M BallantyneSalim S ViraniPublished in: Cardiovascular drugs and therapy (2020)
The development of new biologics targeting lipid risk factors will provide clinicians additional tools to reduce the risk for ASCVD. Important factors to consider will be cost-effectiveness and improving methods to personalize treatments to risk factors.
Keyphrases